BrainXell's BXT-110 Shows Promising Preclinical Results for Parkinson's Disease Cell Therapy
核心洞察
BrainXell (搜索) presents preclinical data for BXT-110 (搜索), an autologous iPSC-derived midbrain dopaminergic progenitor therapy for Parkinson's disease (搜索), showing over 75% FOXA2 (搜索)+/OTX2 (搜索)+ expression and greater than 60% graft survival in vivo.
The therapy demonstrated significant behavioral recovery within 12 weeks post-transplantation in rodent models, supporting its potential as a disease-modifying treatment for Parkinson's disease (搜索).
BrainXell (搜索) also showcased advances in CNS modeling platforms, including a 3D blood-brain barrier model and accelerated oligodendrocyte differentiation protocols reaching over 95% purity within 30 days.
BrainXell (搜索), Inc. announced promising preclinical data for its lead cell therapy candidate BXT-110 (搜索) at the 2025 Society for Neuroscience Annual Meeting in San Diego, marking significant progress in the development of regenerative treatments for Parkinson's disease (搜索).
BXT-110 Demonstrates Strong Preclinical Efficacy
The company's flagship therapy, BXT-110 (搜索), is an autologous iPSC-derived midbrain dopaminergic progenitor (mDAP) therapy designed to address the underlying neuronal loss in Parkinson's disease (搜索). Preclinical data revealed that BXT-110 achieved more than 75 percent FOXA2 (搜索)+/OTX2 (搜索)+ expression, indicating successful specification of midbrain dopaminergic cell fate. The therapy also generated over 60% TH (搜索)+ neurons in vitro, demonstrating robust dopaminergic neuron differentiation.
Critically, in vivo studies showed greater than 60 percent graft survival, a key metric for cell therapy success. Functional efficacy was demonstrated in rodent models, where BXT-110 (搜索) produced significant behavioral recovery within 12 weeks post-transplantation, supporting its potential as a disease-modifying therapy for Parkinson's disease (搜索).
"BrainXell (搜索) is at the forefront of the biotechnology industry, engineering novel cellular platforms for biomedical discovery and pharmaceutical development, as well as developing personalized regenerative therapy for devastating neurological diseases," stated Dr. Su-Chun Zhang, BrainXell Founder and Advising Chief Scientific Officer.
Advanced CNS Modeling Platforms
Beyond its therapeutic pipeline, BrainXell (搜索) showcased several technological advances in central nervous system modeling. The company has engineered a 3D neurovascular microfluidic model of the human blood-brain barrier using a tri-culture system of endothelial cells, astrocytes, and pericytes. This platform accurately replicates barrier integrity and permeability, providing a quantitative tool for CNS drug transport and safety studies.
Accelerated Cell Differentiation Protocols
BrainXell (搜索) scientists have developed an accelerated differentiation protocol for human iPSC-derived oligodendrocyte progenitor cells, achieving more than 95 percent O4+ purity within 30 days. These cells express key myelin markers including MBP, MOG (搜索), and PLP1 (搜索). When integrated into 3D co-cultures, the oligodendrocytes exhibited enhanced arborization and myelination, offering new research tools for studying remyelination processes.
Multilineage Neural Modeling
The company has also created multilineage 3D neural spheroids that integrate neurons, astrocytes, and microglia. These sophisticated models demonstrate coordinated network activity, synaptic signaling, and neuroinflammatory responses, advancing physiologically relevant platforms that bridge the gap between in vitro assays and in vivo biology.
Company Background
BrainXell (搜索) operates through two entities: BrainXell, Inc. in Madison, Wisconsin, and BrainXell Therapeutics in San Diego, California. Founded by Dr. Su-Chun Zhang, a recognized leader in stem-cell neuroscience, the company integrates scientific excellence with manufacturing innovation to accelerate understanding and treatment of CNS diseases. The company's approach spans scalable cell-based assays, advanced disease modeling, and next-generation cell therapies for neurodegenerative disorders (搜索).